Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects

Inclusion Criteria:

- In good health, determined by no clinically significant findings from medical history,
physical examination, 12-lead ECG, vital signs measurements, and clinical laboratory
evaluations

- Body Mass index between 18 and 30.0 kg/m2

- Able to comply with all the trial procedures

- females will not be pregnant or lactating

- If female of childbearing potential or male agree to use contraception as defined in
the protocol

- Male subjects must also be willing to refrain from donating sperm from trial Check-in
until 90 days after the last dose

Exclusion Criteria:

- Significant history or clinical manifestation of any metabolic, allergic,
dermatological, hepatic, renal, hematological, pulmonary, cardiovascular,
gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder

- History of significant hypersensitivity, intolerance, or allergy to any drug compound,
food, or other substance

- History of bowel obstruction, stomach or intestinal surgery or resection that would
potentially alter absorption and/or excretion of orally administered drugs
(uncomplicated appendectomy and/or cholecystectomy or hernia repair will be allowed).

- Clinically significant abnormality on 12-lead ECG

- Clinically significant abnormality in hematology, clinical chemistry, or urinalysis

- History of alcoholism or drug/chemical abuse within 2 years

- Alcohol consumption of > 21 units per week for males and > 14 units for females

- Positive urine drug screen

- Positive hepatitis panel and/or positive human immunodeficiency test

- Receipt of any investigational product within 30 days or 5 half-lives

- Previous exposure to GLP-1, GLP-2, human growth hormone, or analogs thereof 30 days
prior to Check-in

- Use or intend to use any medications/products known to be strong inhibitors or strong
inducers of cytochrome P450 3A enzyme, including St. John's wort

- Use of tobacco, smoking cessation products, or products containing nicotine (including
but not limited to cigarettes, e-cigarettes, pipes, cigars, chewing tobacco, nicotine
lozenges, or nicotine gum ) within 3 months prior to Screening

- Receipt of blood products within 2 months prior to Check-in and throughout the trial.

- Donation of blood or significant blood loss from 56 days prior to Screening, plasma
from 2 weeks prior to Screening, or platelets from 6 weeks prior to Screening and
throughout the trial.

- Poor peripheral venous access.